Literature DB >> 7719931

Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays.

M Printz1, J Reynolds, S J Mento, D Jolly, K Kowal, N Sajjadi.   

Abstract

Many protocols for gene therapy employ recombinant retroviral vectors, which are replication-defective retroviruses engineered to serve as gene delivery vehicles. The use of retroviral vectors for human gene therapy requires careful screening of vector-producing cell lines and culture supernatants to ensure the absence of replication competent retrovirus (RCR) in clinical products. In this study we have examined several different culture assays routinely used to test for the presence of RCR. Results indicate that cocultivation of a vector-producing cell line with a permissive cell line can reproducibly detect a low level of contaminating RCR. RCR was detected less frequently in direct tests of cell-free culture supernatants from a contaminated vector-producing line. Further studies revealed that recombinant retroviral vector can interfere, to varying degrees, with the detection of low-level RCR in culture supernatants when a marker rescue assay, an extended mink S+L- assay or a PG-4 S+L- assay is used. Interference can be partially overcome by culturing the vector preparation with a permissive cell line for several days before testing on the indicator cell line. The interference phenomenon we have observed may also occur in other culture assays routinely used for the detection of RCR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719931

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  4 in total

1.  Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes.

Authors:  A Bosch; P B McCray; S M Chang; T R Ulich; W S Simonet; D J Jolly; B L Davidson
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

2.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

3.  A reporter system for replication-competent gammaretroviruses: the inGluc-MLV-DERSE assay.

Authors:  A L Aloia; L Duffy; V Pak; K E Lee; S Sanchez-Martinez; D Derse; G Heidecker; K Cornetta; A Rein
Journal:  Gene Ther       Date:  2012-03-08       Impact factor: 5.250

4.  Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.

Authors:  Kenneth Cornetta; Lisa Duffy; Steven A Feldman; Crystal L Mackall; Marco L Davila; Kevin J Curran; Richard P Junghans; Jean Yuh Tang; James N Kochenderfer; Roisin O'Cearbhaill; Gary Archer; Hans-Peter Kiem; Nirali N Shah; Cindy Delbrook; Rosie Kaplan; Renier J Brentjens; Isabelle Rivière; Michel Sadelain; Steven A Rosenberg
Journal:  Mol Ther Methods Clin Dev       Date:  2018-08-17       Impact factor: 6.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.